Clinical Trials Logo

Coenzyme Q10 clinical trials

View clinical trials related to Coenzyme Q10.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04302532 Completed - Coenzyme q10 Clinical Trials

Coenzyme q 10 and Fertility Outcome in Women With Clomiphene Resistant PCOS

Start date: July 1, 2020
Phase: Phase 4
Study type: Interventional

The study evaluates the effect of coenzyme q 10 on ovulation and subsequent pregnancy in women with polycystic ovarian syndrome. Half of the participants will receive coq10 and ovulation induction with clomiphene and other half would receive a placebo with clomiphene.

NCT ID: NCT03893864 Completed - Aging Clinical Trials

Bioavailability and Impact of Coenzyme Q10 in Stressing Exercise in Senescence Athletes

CoQ10Sport
Start date: March 1, 2018
Phase: Phase 1
Study type: Interventional

It is proposed to establish a group of subjects composed of 10 healthy individuals of> 50 years and <65, physically active, without metabolic or inflammatory pathology. All of them will undergo a health examination and the physical condition and the absence of contraindication of the sports practice will be characterized through a monitored effort test. Each subject will take a capsule of coenzyme Q10® INDENA for 30 days. The dose to be administered is 100 mg/d of CoQ10 a with food (noon). The state of physical condition and the biochemical and biological variables that reflect oxidative stress and mitochondrial functioning before and after the intervention will be measured.

NCT ID: NCT02865460 Completed - Gulf War Illness Clinical Trials

Coenzyme Q10 Phase III Trial in Gulf War Illness

Start date: July 24, 2017
Phase: Phase 3
Study type: Interventional

The primary objective of this clinical trial is to determine if treatment with ubiquinol, a form of coenzyme Q10, improves the physical function of men and women Veterans suffering from Gulf War Illness (GWI). The primary outcome measure is a change from baseline on the Short Form Health Survey 36-item (SF-36), with respect to physical functioning and symptoms. Secondary outcome measures include changes from baseline levels on GWI-associated biomarkers in peripheral blood and GWI-associated symptoms of chronic pain, fatigue, insomnia, activity level, and cognitive and mental functioning.